VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Nature Medicine2017Vol. 23(5), pp. 551–555
Citations Over TimeTop 1% of 2017 papers
Jianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Z. Shi, Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, Patricia Troncoso, James P. Allison, Christopher J. Logothetis, Ignacio I. Wistuba, Manuel A. Sepúlveda, Jingjing Sun, Jennifer A. Wargo, Jorge Blando, Padmanee Sharma
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma(2019)17 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)